Intellia Therapeutics (NTLA) Return on Sales (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Return on Sales data on file, last reported at 0.06% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.06%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.06% (up 5.0% YoY), and the FY2025 annual result was 0.06%, up 2.0% from the prior year.
• Return on Sales eased to 0.06% in Q1 2026 per NTLA's latest filing, from 0.04% in the prior quarter.
• Over five years, Return on Sales peaked at 0.66% in Q4 2023 and troughed at 0.18% in Q2 2024.
• A 5-year average of 0.04% and a median of 0.08% in 2022 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2024: Return on Sales jumped 231 bps in 2022, then tumbled 76 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 0.08% in 2022, then surged by 961 bps to 0.66% in 2023, then plunged by 115 bps to 0.1% in 2024, then surged by 59 bps to 0.04% in 2025, then sank by 58 bps to 0.06% in 2026.
• Business Quant data shows NTLA's Return on Sales at 0.06% in Q1 2026, 0.04% in Q4 2025, and 0.08% in Q3 2025.